Excellent progress !!!
Celera Corporation (NASDAQ:CRA) a health care company focused on medical therapies, developing dianostic related products has entered in to exclusive licenses agreement to use Cellmid- CDY (previously MTY) patent portfolio for the development of lung cancer diagnostics.
Cellmid Limited (ASX:CDY) is a listed Australian biotechnology company committed to the commercialization of midkine, a heparin-binding growth factor, and its inhibitors for both therapeutic and diagnostic applications.
CDY is actively looking for partners to commercialise the Company’s significant anti-midkine antibody portfolio for diagnostic and therapeutic purposes. In addition, CDY will also be looking for partnerships to continue to research anti-midkine antisense and siRNA.
CDY holds the largest intellectual property portfolio globally in relation to midkine, a significant therapeutic and diagnostic target !!!!!!
Ann: $3.63 Million Capital Raising Completed , page-3
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| AN1 (ASX) Chart |
Day chart unavailable